SG10201700289RA - Calicheamicin derivative-carrier conjugates - Google Patents

Calicheamicin derivative-carrier conjugates

Info

Publication number
SG10201700289RA
SG10201700289RA SG10201700289RA SG10201700289RA SG10201700289RA SG 10201700289R A SG10201700289R A SG 10201700289RA SG 10201700289R A SG10201700289R A SG 10201700289RA SG 10201700289R A SG10201700289R A SG 10201700289RA SG 10201700289R A SG10201700289R A SG 10201700289RA
Authority
SG
Singapore
Prior art keywords
carrier conjugates
calicheamicin derivative
calicheamicin
derivative
conjugates
Prior art date
Application number
SG10201700289RA
Other languages
English (en)
Inventor
Kunz Arthur
Keith Moran Justin
Thomas Rubino Joseph
Jain Neera
Joseph Vidunas Eugene
Mclean Simpson John
David Robbins Paul
Merchant Nishith
Francis Dijoseph John
Edward Ruppen Mark
Krishnaji Damle Nitin
George Popplewell Andrew
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201700289R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SG10201700289RA publication Critical patent/SG10201700289RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
SG10201700289RA 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates SG10201700289RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37744002P 2002-05-02 2002-05-02

Publications (1)

Publication Number Publication Date
SG10201700289RA true SG10201700289RA (en) 2017-02-27

Family

ID=29401497

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201700289RA SG10201700289RA (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates
SG200607459-5A SG165158A1 (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates
SG2011035912A SG187991A1 (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG200607459-5A SG165158A1 (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates
SG2011035912A SG187991A1 (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates

Country Status (33)

Country Link
US (6) US8153768B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP1507556B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (5) JP5153057B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR101125524B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN100482277C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2003231293A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2017C049I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (3) BR122019027974B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2483552A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (3) CR7557A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (4) CY1116634T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (3) DK3127553T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP045445A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2545745T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR17C1054I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (4) HUE030806T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL164946A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (3) LT1507556T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LUC00044I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04010792A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300903I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO339730B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (2) NZ573563A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (2) PH12013501159A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (5) PL228741B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (3) PT1507556T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (3) RU2422157C3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (3) SG10201700289RA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (3) SI2371392T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TWI438010B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA88599C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003092623A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (2) ZA200409752B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20110045005A1 (en) * 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
CA2483552A1 (en) * 2002-05-02 2003-11-13 Wyeth Holdings Corporation Calicheamicin derivative-carrier conjugates
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
EP1759582B1 (en) * 2004-05-26 2016-11-23 National University Corporation Kagawa University Preservative solution for cells, tissues and organs comprising rare sugar and preservation method with the use of the same
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
CA2486285C (en) * 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
RU2007108716A (ru) * 2004-09-10 2008-10-20 Вайет (Us) Гуманизированные антитела к антигену 5т4 и конъюгаты гуманизированного антитела к антигену 5т4 с калихеамицином
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
CA2618723C (en) 2005-08-16 2014-05-27 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
PT1928503E (pt) 2005-08-24 2012-10-19 Immunogen Inc Processo para preparação de conjugados de anticorpo e maitansinóide
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US9393215B2 (en) 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
WO2007067602A1 (en) * 2005-12-06 2007-06-14 Wyeth Interleukin-11 compositions and methods of use
NZ571208A (en) 2006-03-10 2011-12-22 Wyeth Corp Anti-5T4 antibodies and uses thereof
ES2371085T3 (es) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
DK2495307T5 (en) 2006-07-13 2018-07-16 Wyeth Llc Preparation of coagulation factor IX with improved glycosylation pattern
RU2475478C2 (ru) 2006-08-21 2013-02-20 Синта Фармасьютиклз Корп. Соединения для лечения пролиферативных расстройств
BRPI0719250A2 (pt) * 2006-10-12 2015-06-16 Wyeth Corp Métodos e composições com opalescência reduzida.
EP2395077A1 (en) 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
CN101626782B (zh) * 2006-12-01 2013-03-27 梅达雷克斯公司 结合cd22的人抗体及其用途
EP2117601A2 (en) * 2006-12-22 2009-11-18 The Regents of the University of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
CN101687916A (zh) * 2007-01-16 2010-03-31 惠氏公司 通过trem-1的炎症治疗、检测和监控
PL2115126T3 (pl) 2007-03-02 2015-08-31 Wyeth Llc Zastosowanie miedzi i glutaminianu w hodowli komórkowej do wytwarzania polipeptydów
HUE039657T2 (hu) * 2007-05-22 2019-01-28 Wyeth Llc Továbbfejlesztett eljárás hidrazidok elõállítására
PE20090309A1 (es) * 2007-06-04 2009-04-18 Wyeth Corp Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
DK2211904T3 (en) * 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
WO2009086072A2 (en) * 2007-12-21 2009-07-09 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients
CA2710453C (en) * 2007-12-26 2019-07-02 Biotest Ag Agents targeting cd138 and uses thereof
CN101945892B (zh) * 2007-12-26 2017-11-24 生物测试股份公司 用于改进对表达cd138的肿瘤细胞的靶向的方法和试剂
PL2242772T3 (pl) * 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
JP2011507933A (ja) * 2007-12-26 2011-03-10 バイオテスト・アクチエンゲゼルシヤフト 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法
US20090186026A1 (en) * 2008-01-18 2009-07-23 Wyeth Ephrin and eph receptor agonists for modulation of bone formation and resorption
WO2009124109A1 (en) * 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
FR2930443B1 (fr) * 2008-04-29 2010-06-25 Oreal Produit extemporane de soin a base d'un lyophilisat de microorganisme et de tensioactif(s) de hlb superieur ou egal a 12
KR101892411B1 (ko) 2008-04-30 2018-08-27 이뮤노젠 아이엔씨 가교제 및 그 용도
TR201907573T4 (tr) * 2009-06-03 2019-06-21 Immunogen Inc Konjugasyon yöntemleri̇
US20130012916A1 (en) * 2010-02-11 2013-01-10 Glide Pharmaceutical Technologies Limited Delivery of immunoglobulin variable domains and constructs thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
ES2862955T5 (en) 2010-10-01 2025-01-29 Modernatx Inc Engineered nucleic acids and methods of use thereof
EP2637692A4 (en) 2010-11-12 2014-09-10 Scott & White Healthcare ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
US8512679B2 (en) * 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
EP2691155B1 (en) 2011-03-29 2018-11-14 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
CA2845585C (en) 2011-08-30 2020-02-18 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4015005A1 (en) 2011-10-03 2022-06-22 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
HK1198657A1 (en) 2011-10-21 2015-05-22 辉瑞公司 Addition of iron to improve cell culture
ES2684950T3 (es) 2011-12-08 2018-10-05 Biotest Ag Usos de inmunoconjugados dirigidos a CD138
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
CA2868438A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
NZ703423A (en) 2012-07-03 2018-02-23 Univ Washington Antibodies to tau
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
EP2935259B1 (en) 2012-12-21 2018-12-19 BioAlliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
WO2014113203A1 (en) 2013-01-17 2014-07-24 Case Western Reserve University Viral nanoparticle multimers
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MY192404A (en) * 2013-05-02 2022-08-19 Hoffmann La Roche Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN105683159B (zh) * 2013-11-04 2017-12-19 辉瑞大药厂 用于合成加利车霉素衍生物的中间体和方法
EP3065780A1 (en) 2013-11-04 2016-09-14 Pfizer Inc. Anti-efna4 antibody-drug conjugates
FI3122757T3 (fi) 2014-02-28 2023-10-10 Hangzhou Dac Biotech Co Ltd Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
WO2015140708A1 (en) 2014-03-19 2015-09-24 Pfizer Inc. Method of cell culture
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
CN106661124A (zh) 2014-06-20 2017-05-10 荷商台医(有限合伙)公司 抗叶酸受体α(FRA)抗体‑药物缀合物及其使用方法
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US9925281B2 (en) 2014-08-05 2018-03-27 Case Western Reserve University Coated plant virus imaging agents
EP3215520B1 (en) 2014-11-07 2022-01-05 Case Western Reserve University Cancer immunotherapy using virus particles
WO2016164578A1 (en) 2015-04-07 2016-10-13 Memorial Sloan Kettering Cancer Center Nanoparticle immunoconjugates
PE20180599A1 (es) * 2015-04-21 2018-04-09 Abbvie Stemcentrx Llc Construcciones de calicheamicina y sus metodos de uso
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
CN107849148B (zh) 2015-05-21 2023-09-19 哈普恩治疗公司 三特异性结合蛋白质及使用方法
US10624975B2 (en) 2015-06-29 2020-04-21 Case Western Reserve University Anticancer drug-containing plant virus particles
CN108024535A (zh) 2015-07-02 2018-05-11 大塚制药株式会社 冻干药物组合物
JP6759326B2 (ja) 2015-07-12 2020-09-23 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 細胞結合分子の共役のための架橋連結体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
EP3322485B1 (en) * 2015-07-16 2020-07-01 Case Western Reserve University Plant virus particles for delivery of antimitotic agents
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
US10738334B2 (en) 2015-09-23 2020-08-11 Pfizer Inc. Cells having reduced BCAT1
KR20180073693A (ko) 2015-11-09 2018-07-02 브리스톨-마이어스 스큅 컴퍼니 Cho 세포에서 생산되는 폴리펩티드의 품질 속성을 조작하는 방법
RU2766000C2 (ru) 2016-01-08 2022-02-07 АльтруБио Инк. Четырехвалентные антитела к psgl-1 и их применения
US20170281758A1 (en) * 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
AU2017247701B2 (en) 2016-04-05 2022-11-10 Pfizer Inc. Cell culture process
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
WO2018017985A1 (en) 2016-07-21 2018-01-25 Case Western Reserve University Plant virus or virus-like particle constructs
CA3042695A1 (en) 2016-11-03 2018-05-11 Case Western Reserve University Melt processed viral nanoparticle constructs
EP3538080A4 (en) 2016-11-14 2020-07-08 Hangzhou Dac Biotech Co., Ltd. CONJUGATION LINERS, MEDICAMENT-MOLECULE CONJUGATES TO A CELL CONTAINING THE SAME, METHODS OF PREPARING AND USING SUCH CONJUGATES WITH THE BINDERS
US11590183B2 (en) 2017-03-10 2023-02-28 Case Western Reserve University Cancer immunotherapy using virus particles
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018213587A1 (en) 2017-05-17 2018-11-22 Case Western Reserve University Anticancer trail-targeted plant virus particles
EP3661522A2 (en) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
US20200255785A1 (en) 2017-09-15 2020-08-13 Bristol-Myers Squibb Company Online biomass capacitance monitoring during large scale production of polypeptides of interest
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019084555A1 (en) 2017-10-27 2019-05-02 Case Western Reserve University TYMOVIRUS VIRUSES AND VIRAL TYPE PARTICLES USEFUL AS NANOVECTORS FOR IMAGING AND THERAPEUTIC AGENTS
US12325875B2 (en) 2018-03-16 2025-06-10 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
MA51453A (fr) * 2018-05-30 2020-09-23 Abbvie Stemcentrx Llc Conjugués anticorps anti-sez6-médicaments et procédés d'utilisation
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
JP7699542B2 (ja) 2018-11-20 2025-06-27 コーネル ユニバーシティー 放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
WO2020115655A1 (en) 2018-12-06 2020-06-11 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
CA3127142A1 (en) * 2019-02-13 2020-08-20 Coimmune, Inc. Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies
AU2020242284A1 (en) 2019-03-19 2021-09-16 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy for the treatment of cancer
US11390853B2 (en) 2019-04-26 2022-07-19 Case Western Reserve University Freeze dried viral nanoparticle constructs
CA3146379A1 (en) * 2019-07-08 2021-01-14 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US11896676B2 (en) 2019-08-07 2024-02-13 Case Western Reserve University Targeting cancer cells and tissue using filamentous plant virus particles
US20230071019A1 (en) * 2019-12-04 2023-03-09 The Research Foundation For The State University Of New York Compositions and methods for reducing off-target toxicity of antibody drug conjugates
US11529430B2 (en) 2019-12-20 2022-12-20 Case Western Reserve University Polydopamine decorated tobacco mosaic theranostic virus nanoparticles
US12203073B2 (en) 2019-12-20 2025-01-21 Case Western Reserve University Plant viral RNA delivery nanoparticles and uses thereof
EP4178611A1 (en) 2020-07-07 2023-05-17 BioNTech SE Therapeutic rna for hpv-positive cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
CN112724263B (zh) * 2021-04-02 2021-08-03 上海偌妥生物科技有限公司 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
EP4473096A1 (en) 2022-02-02 2024-12-11 Pfizer Inc. Cysteine prototrophy
JPWO2024058201A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2022-09-16 2024-03-21
KR20250089547A (ko) 2022-10-25 2025-06-18 펩토믹, 에스.엘. 암 치료를 위한 조합 요법
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
WO2024218706A1 (en) 2023-04-21 2024-10-24 Pfizer Inc. Improved cells and cell cultures
TW202502371A (zh) 2023-06-07 2025-01-16 瓦爾希伯倫私人腫瘤研究基金會 用於治療癌症的與ｂｒａｆ抑制劑的組合療法
WO2024251846A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with mek inhibitors for the treatment of cancer
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
WO2025063789A1 (ko) * 2023-09-21 2025-03-27 주식회사 피노바이오 운반체-약물 접합체 및 dnmt-1 저해제의 병용 요법
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU8221191A (en) 1990-06-27 1992-01-23 Princeton University Probes for detecting mutant p53
JP3854306B2 (ja) 1991-03-06 2006-12-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒト化及びキメラモノクローナル抗体
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5712474A (en) * 1993-09-29 1998-01-27 Canon Kabushiki Kaisha Image processing apparatus for correcting blurring of an image photographed by a video camera
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
WO1996005306A2 (en) 1994-08-12 1996-02-22 Myriad Genetics, Inc. IN VIVO MUTATIONS AND POLYMORPHISMS IN THE 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE
CA2195557C (en) 1994-08-12 2006-10-17 Shui-On Leung Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US7541034B1 (en) 1997-03-20 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3919235B2 (ja) * 1997-06-13 2007-05-23 ジェネンテク，インコーポレイテッド 抗体製剤
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US6183477B1 (en) * 1998-09-04 2001-02-06 Smith & Nephew, Inc. Attachment tool for drill guide
KR100345463B1 (ko) 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
JP2000226336A (ja) * 1998-11-30 2000-08-15 Sankyo Co Ltd 免疫グロブリン製剤
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
WO2000074718A1 (en) * 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
WO2001012653A1 (en) * 1999-08-17 2001-02-22 Novo Nordisk A/S Stabilisation of freeze-dried cake
BR0014734A (pt) 1999-10-12 2002-06-18 Connex Ges Zur Optimierung Von Método melhorado para detectar microorganismos resistentes a ácido na evacuação
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
CA2483552A1 (en) 2002-05-02 2003-11-13 Wyeth Holdings Corporation Calicheamicin derivative-carrier conjugates

Also Published As

Publication number Publication date
EP1507556A2 (en) 2005-02-23
ES2545745T3 (es) 2015-09-15
PL228741B1 (pl) 2018-05-30
CR20120364A (es) 2012-10-05
PL222725B1 (pl) 2016-08-31
PT1507556T (pt) 2016-09-28
NO2017061I1 (no) 2017-11-21
US9351986B2 (en) 2016-05-31
LTPA2017036I1 (lt) 2017-11-27
JP2017105801A (ja) 2017-06-15
PL410218A1 (pl) 2015-03-30
ZA201003874B (en) 2019-12-18
TW200404005A (en) 2004-03-16
PH12013501159B1 (en) 2015-12-02
EP2371392B1 (en) 2015-07-08
DK1507556T3 (en) 2016-09-12
RU2678818C2 (ru) 2019-02-04
US8153768B2 (en) 2012-04-10
US20040192900A1 (en) 2004-09-30
RU2016141576A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-05-03
AU2009202609A1 (en) 2009-07-16
PL411824A1 (pl) 2015-08-17
RU2602878C2 (ru) 2016-11-20
LT1507556T (lt) 2016-10-10
RU2422157C2 (ru) 2011-06-27
EP2371392A1 (en) 2011-10-05
US20160303252A1 (en) 2016-10-20
PT3127553T (pt) 2022-01-24
RU2422157C3 (ru) 2021-04-23
NO20044663L (no) 2005-01-25
ZA200409752B (en) 2010-08-25
JP2015061875A (ja) 2015-04-02
US20040082764A1 (en) 2004-04-29
PL224844B1 (pl) 2017-02-28
SI3127553T1 (sl) 2022-02-28
NL300903I2 (nl) 2018-02-08
HK1070825A1 (en) 2005-06-30
WO2003092623A3 (en) 2004-03-18
NO20161431A1 (no) 2005-01-25
RU2011108928A (ru) 2012-09-20
US8835611B2 (en) 2014-09-16
CA2483552A1 (en) 2003-11-13
ES2593304T3 (es) 2016-12-07
KR20110050753A (ko) 2011-05-16
BRPI0309868B8 (pt) 2021-05-25
ECSP045445A (es) 2005-01-28
CY1116634T1 (el) 2017-03-15
NZ586071A (en) 2012-02-24
BR122019027966B8 (pt) 2021-07-27
DK2371392T3 (en) 2015-08-31
MXPA04010792A (es) 2005-03-07
FR17C1054I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-01-12
JP5756489B2 (ja) 2015-07-29
LUC00044I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-02-26
NZ573563A (en) 2010-10-29
HUS1700038I1 (hu) 2017-11-28
BR0309868A (pt) 2005-10-18
KR101125524B1 (ko) 2012-03-22
NO339730B1 (no) 2017-01-23
LT3127553T (lt) 2022-04-11
KR101062628B1 (ko) 2011-09-07
JP2013163678A (ja) 2013-08-22
DK3127553T3 (da) 2022-01-31
CN100482277C (zh) 2009-04-29
BR122019027974B1 (pt) 2022-06-14
TWI438010B (zh) 2014-05-21
CY2017035I2 (el) 2018-04-04
SI2371392T1 (sl) 2015-10-30
US8747857B2 (en) 2014-06-10
PH12013501159A1 (en) 2015-12-02
SI1507556T1 (sl) 2016-10-28
PH12013501158A1 (en) 2015-11-09
BRPI0309868B1 (pt) 2020-04-28
HUE057124T4 (hu) 2022-02-28
ES2916174T3 (es) 2022-06-28
CR7557A (es) 2008-10-03
PL224150B1 (pl) 2016-11-30
LUC00044I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-11-03
HUE030806T2 (hu) 2017-05-29
WO2003092623A2 (en) 2003-11-13
IL230659A (en) 2016-02-29
JP5153057B2 (ja) 2013-02-27
US20180339058A1 (en) 2018-11-29
AU2003231293A1 (en) 2003-11-17
PL374523A1 (en) 2005-10-31
PT2371392E (pt) 2015-10-07
IL230659A0 (en) 2014-03-31
EP3127553A1 (en) 2017-02-08
IL164946A (en) 2015-06-30
PL224001B1 (pl) 2016-11-30
PL410219A1 (pl) 2015-03-30
CN1665532A (zh) 2005-09-07
FR17C1054I2 (fr) 2019-01-11
TWI379693B (en) 2012-12-21
BR122019027966B1 (pt) 2020-11-17
RU2602878C3 (ru) 2021-11-24
LTC2371392I2 (lt) 2019-03-25
IL164946A0 (en) 2005-12-18
CY1124900T1 (el) 2023-01-05
AU2009202609B2 (en) 2012-07-26
CR20130390A (es) 2013-11-08
BE2017C049I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-08-09
CA2871117A1 (en) 2003-11-13
CY1117973T1 (el) 2017-05-17
PH12013501158B1 (en) 2015-11-09
HUE057124T2 (hu) 2022-04-28
US20120213804A1 (en) 2012-08-23
US20140235835A1 (en) 2014-08-21
RU2016141576A (ru) 2018-05-03
KR20050006220A (ko) 2005-01-15
TW201231089A (en) 2012-08-01
JP6872376B2 (ja) 2021-05-19
UA88599C2 (ru) 2009-11-10
JP2012051900A (ja) 2012-03-15
EP1507556A4 (en) 2009-01-07
NO344509B1 (no) 2020-01-20
SG165158A1 (en) 2010-10-28
HK1162926A1 (en) 2012-09-07
RU2004135101A (ru) 2005-06-27
EP3127553B1 (en) 2021-12-01
SG187991A1 (en) 2013-03-28
CY2017035I1 (el) 2018-04-04
PL413302A1 (pl) 2016-05-23
HUE027590T2 (hu) 2016-11-28
EP1507556B1 (en) 2016-07-27
JP5441971B2 (ja) 2014-03-12
JP2005524700A (ja) 2005-08-18

Similar Documents

Publication Publication Date Title
HUS1700038I1 (hu) Calicheamicin származék-hordozó konjugátumok
EP1608735A4 (en) RNAI CONJUGATES
AU2003276494A8 (en) Functional sites
SI1596887T1 (sl) Konjugati polimer-del faktorja VIII
AU2003253048A1 (en) Tubulysin conjugates
EP1494693A4 (en) SPECIFIC ANTIBODIES TO CRIPTO
GB0209896D0 (en) Conjugate
AU2003278857A8 (en) Oligonucleotide conjugates
EP1482957A4 (en) ANTIBIOTIC CONJUGATES
GB0119665D0 (en) Conjugates
ZA200500199B (en) Immunogenic conjugates
GB0221778D0 (en) Conjugate
AU2003292197A8 (en) Lna-cpg conjugates
GB0426103D0 (en) Retention mechanism
GB0217672D0 (en) Powerdrive
AU7426601A (en) Gene-regulating conjugates
IL163551A0 (en) Antibiotic conjugates
HK1076040A (en) Ghrelin-carrier conjugates
GB0211890D0 (en) Device II
GB0226009D0 (en) Envelopes
GB0102530D0 (en) Tidal rater
GB0208542D0 (en) Guide
AU150609S (en) Weephole former